Vascepa and Azelastine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Vascepa (icosapent ethyl) and Azelastine (azelastine hydrochloride). Common drug interactions include impaired work ability among females and gait disturbance among males.

The phase IV clinical study analyzes what interactions people have when they take Vascepa and Azelastine. It is created by eHealthMe based on reports of 51 people who take the same drugs from the FDA, and is updated regularly.

What is Vascepa?

Vascepa has active ingredients of icosapent ethyl. It is often used in high blood cholesterol. eHealthMe is studying from 5,894 Vascepa users. Check the latest studies of Vascepa.

What is Azelastine?

Azelastine has active ingredients of azelastine hydrochloride. It is often used in allergies. eHealthMe is studying from 17,400 Azelastine users. Check the latest studies of Azelastine.

On Aug, 12, 2026

51 people who take Vascepa and Azelastine together, and have interactions are studied.

Vascepa and Azelastine drug interactions.

What are the common drug interactions of Vascepa and Azelastine, by gender? *:

female:

Impaired work ability
Influenza
Infusion site pruritus (severe itching at infusion site)
Infusion site swelling
Infusion site urticaria (rash of round, red welts on the skin at infusion site)
Insomnia (sleeplessness)
Kidney infection
Mouth ulceration (mouth ulcers)
Nasopharyngitis (inflammation of the nasopharynx)
Nausea (feeling of having an urge to vomit)

male:

Gait disturbance
Asthenia (weakness)
Chronic kidney disease
Cough
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
Abdominal discomfort
Cardiac disorder
Diarrhoea
Gout (uric acid crystals building up in the body)

What are the common drug interactions of Vascepa and Azelastine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Chronic kidney disease
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
Nephrogenic anaemia (anaemia due to kidney disease)
Renal failure (kidney dysfunction)
Renal injury (kidney injury)

50-59:

Asthenia (weakness)
Blood glucose decreased
Blood glucose fluctuation
Dizziness
Gait disturbance
Hypoglycaemia (deficiency of glucose in the bloodstream)
Neuropathy peripheral (surface nerve damage)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Sinus disorder (disease of sinus)
Sinusitis (inflammation of sinus)

60+:

Back pain
Cardiac disorder
Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
Cough
Death
Dizziness
Gastrointestinal disorder (functional problems of gastrointestinal tract)
Headache (pain in head)
Infusion related reaction
Local reaction (reaction of any substance at the site of use)

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 12 people, 23.53%
Asthma: 7 people, 13.73%
Hypersensitivity: 6 people, 11.76%
Pain: 5 people, 9.80%
Lipodystrophy Acquired (a regional loss of subcutaneous adipose tissue which usually starts in the face, extends downward acquired): 5 people, 9.80%
High Blood Pressure: 5 people, 9.80%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 9.80%
Blood Pressure Abnormal: 5 people, 9.80%
Indigestion: 4 people, 7.84%
Nasal Disorder (diseases of nose): 3 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Vascepa and Azelastine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously